All articles tagged with #crossbridge bio
Eli Lilly agreed to acquire Houston-based CrossBridge Bio, a startup focused on antibody-drug conjugates, in a deal worth up to $300 million, expanding Lilly's biotech and ADC capabilities.
Eli Lilly is acquiring CrossBridge Bio in a deal potentially worth $300 million to broaden its portfolio of antibody-drug conjugates, notably dual-payload ADCs like CBB-120 targeting TROP2; the structure of upfront versus milestone payments wasn’t disclosed, and CrossBridge aims to advance its lead candidate into the clinic this year.